

# SINGLE-CENTER REAL-WORLD EXPERIENCE WITH CLADRIBINE, LOW-DOSE CYTARABINE, AND VENETOCLAX (CAV) IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

LF Nasr<sup>1</sup>, JI Haro-Silerio<sup>1</sup>, E Cai<sup>1</sup>, H Turner<sup>1</sup>, NA Balestra<sup>1</sup>, BR Miller<sup>1</sup>, CV West<sup>1</sup>, A Li<sup>1</sup>, TM Nguyen<sup>1</sup>, J Lu<sup>1</sup>, JJ Fraebel,<sup>1</sup> T Abuasab<sup>1</sup>  
1. Baylor College of Medicine, Houston, TX

## INTRODUCTION

- CAV in newly diagnosed (ND) acute myeloid leukemia (AML):
  - high composite complete remission (CR/CRi) rates : 84-94%
  - deep measurable residual disease (MRD) responses : 75-84%.
- Emerging data in relapsed/refractory (R/R) AML
  - CR/CRi rates : 57-69%,
  - Outcomes significantly attenuated with prior venetoclax exposure
- Real-world data outside of clinical trials remain limited.
- This single-center study: CAV in ND and R/R real-world settings.

## METHODS



- 13 adults treated with CAV between 2022 and 2026.
- 6 with ND AML and 7 with R/R AML.
- Baseline characteristics:
  - age,
  - ELN risk category, molecular profile,
  - number of prior lines and prior venetoclax exposure.
- Endpoints:
  - CR/CRi,
  - MRD negativity by flow cytometry, overall survival (OS), allogeneic transplantation, and 30-day mortality.

## CONCLUSIONS

- CAV demonstrated activity in both ND and R/R AML.
- CAV as a potential viable lower-intensity venetoclax-based strategy.
- Limitations:
  - retrospective single-center design
  - small sample size
- Multi-institutional studies are warranted particularly in venetoclax-pretreated populations.

## RESULTS

| Characteristic         | Newly Diagnosed cohort (N=6) | Relapsed / Refractory Cohort (N=7) |
|------------------------|------------------------------|------------------------------------|
| N (%) / median [range] |                              |                                    |
| Age                    | 70 [62-76]                   | 60 (46-75)                         |
| ELN Risk 2024          |                              |                                    |
| Favorable              | 1 (17)                       | 1 (14)                             |
| Intermediate           | 3 (50)                       | 1 (14)                             |
| Adverse                | 2 (33)                       | 5 (72)                             |
| CR/CRi rate            | 5 (83)                       | 3 (50)                             |
| Number of Prior lines  | 0                            | 1 [1-2]                            |
| Prior Venetoclax       | 0                            | 5 (71)                             |



## CONTACT INFORMATION

Tareq Abuasab, 1919 Old Spanish Trail Houston, TX, 77054  
Email: Tareq.Abuasab@bcm.edu